Literature DB >> 26879859

An Exploratory Factor Analysis of a Brief Self-Report Scale to Detect Neurocognitive Impairment Among Participants Enrolled in Methadone Maintenance Therapy.

Michael Copenhaver1, Roman Shrestha2, Jeffrey A Wickersham3, Damian Weikum4, Frederick L Altice5.   

Abstract

The present study examines the factor structure of the existing Neuropsychological Impairment Scale (NIS) through the use of exploratory factor analysis (EFA). The NIS is a brief, self-report measure originally designed to assess neurocognitive impairment (NCI) by having patients rate a range of items that may influence cognitive functioning. Stabilized patients on methadone maintenance therapy (MMT; N=339) in New Haven, CT who reported drug- or sex-related HIV risk behaviors in the past 6 months were administered the full 95-item NIS. An EFA was then conducted using principal axis factoring and orthogonal varimax rotation. The EFA resulted in retaining 57 items, with a 9-factor solution that explained 54.8% of the overall variance. The revised 9-factor measure--now referred to as the Brief Inventory of Neuro-cognitive Impairment (BINI)--showed a diverse set of factors with excellent to good reliability (i.e., F1 α=0.97 to F9 α=0.73). This EFA suggests the potential utility of using the BINI in the context of addiction treatment. Further research should examine the utility of this tool within other clinical care settings.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Addiction; Exploratory factor analysis; HIV; Methadone maintenance therapy; Neurocognitive impairment; Neuropsychological Impairment Scale

Mesh:

Substances:

Year:  2016        PMID: 26879859      PMCID: PMC4775373          DOI: 10.1016/j.jsat.2016.01.002

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  34 in total

1.  Effects of executive function impairment on change processes and substance use outcomes in 12-step treatment.

Authors:  J Morgenstern; M E Bates
Journal:  J Stud Alcohol       Date:  1999-11

2.  Risk behaviors by audio computer-assisted self-interviews among HIV-seropositive and HIV-seronegative injection drug users.

Authors:  Grace E Macalino; David D Celentano; Carl Latkin; Steffanie A Strathdee; David Vlahov
Journal:  AIDS Educ Prev       Date:  2002-10

Review 3.  Intervening effectively with drug abusers infected with HIV: taking into account the potential for cognitive impairment.

Authors:  Michael Copenhaver; S Kelly Avants; Lara A Warburton; Arthur Margolin
Journal:  J Psychoactive Drugs       Date:  2003 Apr-Jun

4.  Evidence of specific cognitive deficits in patients with chronic low back pain under long-term substitution treatment of opioids.

Authors:  Marcus Schiltenwolf; Michael Akbar; Andreas Hug; Ute Pfüller; Simone Gantz; Eva Neubauer; Herta Flor; Haili Wang
Journal:  Pain Physician       Date:  2014 Jan-Feb       Impact factor: 4.965

5.  Effects of moderate alcohol consumption on cognitive function in women.

Authors:  Meir J Stampfer; Jae Hee Kang; Jennifer Chen; Rebecca Cherry; Francine Grodstein
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

6.  Neurocognitive dysfunction in dually-diagnosed patients: a potential roadblock to motivating behavior change.

Authors:  A W Blume; J M Davis; K B Schmaling
Journal:  J Psychoactive Drugs       Date:  1999 Apr-Jun

Review 7.  HIV-1 infection and cognitive impairment in the cART era: a review.

Authors:  Judith Schouten; Paola Cinque; Magnus Gisslen; Peter Reiss; Peter Portegies
Journal:  AIDS       Date:  2011-03-13       Impact factor: 4.177

8.  Cognitive impairment among methadone maintenance patients.

Authors:  S Darke; J Sims; S McDonald; W Wickes
Journal:  Addiction       Date:  2000-05       Impact factor: 6.526

Review 9.  Characterizing the cognitive effects of cocaine: a comprehensive review.

Authors:  Desirée B Spronk; Janelle H P van Wel; Johannes G Ramaekers; Robbert J Verkes
Journal:  Neurosci Biobehav Rev       Date:  2013-07-20       Impact factor: 8.989

10.  Methadone vs. buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls.

Authors:  Pekka Rapeli; Carola Fabritius; Hannu Alho; Mikko Salaspuro; Kristian Wahlbeck; Hely Kalska
Journal:  BMC Clin Pharmacol       Date:  2007-06-12
View more
  12 in total

1.  Rationale and design of an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among opioid-dependent people who use drugs: The CHRP-BB study.

Authors:  Roman Shrestha; Frederick L Altice; Brian Sibilio; Jude Ssenyonjo; Michael M Copenhaver
Journal:  Contemp Clin Trials       Date:  2019-06-20       Impact factor: 2.226

2.  Modeling a Theory-Based Approach to Examine the Influence of Neurocognitive Impairment on HIV Risk Reduction Behaviors Among Drug Users in Treatment.

Authors:  Tania B Huedo-Medina; Roman Shrestha; Michael Copenhaver
Journal:  AIDS Behav       Date:  2016-08

3.  Correlates of willingness to initiate pre-exposure prophylaxis and anticipation of practicing safer drug- and sex-related behaviors among high-risk drug users on methadone treatment.

Authors:  Roman Shrestha; Pramila Karki; Frederick L Altice; Tania B Huedo-Medina; Jaimie P Meyer; Lynn Madden; Michael Copenhaver
Journal:  Drug Alcohol Depend       Date:  2017-02-02       Impact factor: 4.492

4.  A Self-Report Measure to Detect Neurocognitive Impairment among Incarcerated People Living with HIV in Malaysian Context: An Exploratory Factor Analysis.

Authors:  Roman Shrestha; Damian Weikum; Michael Copenhaver; Frederick L Altice
Journal:  Int J Ment Health Addict       Date:  2017-04-03       Impact factor: 3.836

5.  Interest in use of mHealth technology in HIV prevention and associated factors among high-risk drug users enrolled in methadone maintenance program.

Authors:  Roman Shrestha; Pramila Karki; Michael Copenhaver
Journal:  AIDS Care       Date:  2017-05-08

6.  Intent to Use Preexposure Prophylaxis (PrEP), HIV Risk Behaviors, and Self-Report Neurocognitive Symptoms by High-Risk Drug Users: A Mediation Analysis.

Authors:  Roman Shrestha; Pramila Karki; Tania B Huedo-Medina; Michael Copenhaver
Journal:  J Assoc Nurses AIDS Care       Date:  2017-04-19       Impact factor: 1.354

7.  Treatment Engagement Moderates the Effect of Neurocognitive Impairment on Antiretroviral Therapy Adherence in HIV-Infected Drug Users in Treatment.

Authors:  Roman Shrestha; Pramila Karki; Tania B Huedo-Medina; Michael Copenhaver
Journal:  J Assoc Nurses AIDS Care       Date:  2016-09-22       Impact factor: 1.354

8.  Examining the Acceptability of mHealth Technology in HIV Prevention Among High-Risk Drug Users in Treatment.

Authors:  Roman Shrestha; Tania B Huedo-Medina; Frederick L Altice; Archana Krishnan; Michael Copenhaver
Journal:  AIDS Behav       Date:  2017-11

9.  The Influence of Neurocognitive Impairment, Depression, and Alcohol Use Disorders on Health-Related Quality of Life among Incarcerated, HIV-Infected, Opioid Dependent Malaysian Men: A Moderated Mediation Analysis.

Authors:  Roman Shrestha; Damian Weikum; Michael Copenhaver; Frederick L Altice
Journal:  AIDS Behav       Date:  2017-04

10.  Developing a cognitive dysfunction risk score for use with opioid-dependent persons in drug treatment.

Authors:  Michael M Copenhaver; Victoria Sanborn; Roman Shrestha; Colleen B Mistler; Matthew C Sullivan; John Gunstad
Journal:  Drug Alcohol Depend       Date:  2021-04-24       Impact factor: 4.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.